San Mateo, CA (PRWEB) June 06, 2012

Entelos, a premier provider of in silico modeling and simulation products and consulting services that help pharmaceutical and consumer product companies make better decisions in their product development process, modeled the mechanistic effects of cholesteryl ester transfer protein (CETP) inhibitors in its cardiovascular PhysioLab platform and predicted unsuccessful outcomes for several class members at the American Heart Association (AHA) annual meeting in 2011. CETP inhibitors have been considered the next promising group of drugs to enhance the effect of statins in the prevention and treatment of abnormal cholesterol profiles and their impact on cardiovascular disease. Entelos? unique modeling process predicted recent clinical trial results demonstrating that these drugs do not provide significant clinical efficacy over that seen with statin therapy alone.

?Drug companies spend billions of dollars annually sponsoring trials that test drug safety and efficacy in humans,? said Shawn O?Connor, president and CEO of Entelos. ?Despite this, fewer than10% of drugs make it from Phase I to launch. Mechanistic modeling is revolutionizing the time and resources required to understand the effects of new drugs, and is simultaneously reducing the risk to humans who participate in clinical studies. Entelos PhysioLab platforms have been providing accurate predictions that have been relied on by world-class collaborators and clients for over 15 years. Our platforms define mechanisms of action and identify biomarkers for patient response ? streamlining or eliminating the need for trial and error clinical studies ? resulting in sizable cost savings, and time-to-market efficiencies.?

Entelos? CV PhysioLab platform has the capability to assess CETP inhibitors in addition to other marketed therapies and novel therapeutic targets for reducing CV risk. The software, a mechanistic computer model of coronary heart disease (CHD) physiology, simulates the cumulative effects of cholesterol metabolism, inflammation and platelet function on plaque growth in the coronary arteries over time through the dynamic modeling of relevant biological pathways. Statistical methodologies are used to relate predicted changes in plaque characteristics to the likelihood of CHD improvement. Such predictions can rapidly be made for approved or novel compounds and drugs in software- created virtual patients and populations, representing the full diversity of patients observed in the clinic. When the detailed effects of three different CETP inhibitors were represented in the model, simulations predicted no significant difference in outcomes between the control and treatment groups, in a typical phase III event trial in thousands of patients over many years. These outcomes closely aligned with those from actual trials. Under other circumstances, the model might have predicted that changes in patient selection could change trial design resulting in better clinical trial outcomes.

Entelos has fully developed platforms in multiple disease areas in addition to Cardiovascular Disease including: Metabolism (with diabetes and obesity), Rheumatoid Arthritis, Hypertension (with heart and kidney failure), Dermatology, Hematology, Infection, Nutrition, and Veterinary Nutrition.

About Entelos

Entelos is an in silico modeling and simulation software and services company delivering predictive technologies reducing risk, time, and cost of product development for pharmaceutical, biotechnology, nutrition and consumer products customers. The Company?s PhysioLab systems biology platforms generate virtual patient populations providing highly predictive analyses to develop safer and more effective drugs, foods and consumer products. Entelos? understanding of patient variability has significant application to the emerging field of personalized medicine. The Company is headquartered in San Mateo, California. For more information, and to see the AHA poster, please visit http://www.entelos.com.

###

Contact:

Wendy Shelton, 650-572-5430

VP, Corporate Communications

shelton(at)entelos.com